Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era?

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14646
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era? Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Sofosbuvir and Velpatasvir: A Complete Pan-Genotypic Treatment for HCV Patients

Turkish Journal of Gastroenterology
Gastroenterology
2016English

In Vitro Susceptibility of HCV Genotype 1 Through 6 Clinical Isolates to the Pan-Genotypic NS3/4A Inhibitor Voxilaprevir

Journal of Clinical Microbiology
Microbiology
2019English

Ribavirin Dosage in Patients With HCV Genotypes 2 and 3 Who Completed Short Therapy With Peg-Interferon Α-2b and Ribavirin

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2010English

Editorial: Should We Abandon HCV Genotype Testing? Maybe

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Letter: Chronic Hepatitis C Genotype 3 Infection - Still a Hurdle Toward a Direct-Acting Anti-Viral-Induced HCV Cure?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Characterization of Nonrapid Virologic Response Patients Infected With HCV Genotype 1 Who May Relapse After Standard Therapy With Peginterferon Plus Ribavirin

Journal of Viral Hepatitis
VirologyHepatologyInfectious Diseases
2011English

In Vitro Antiviral Profile of Ruzasvir: A Potent and Pan-Genotype Inhibitor of HCV NS5A

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2018English

Editorial: A Psychology of Aging: Who Needs It?

Canadian Journal on Aging
GerontologyGeriatricsHealthHome CareCommunity
1998English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy